1.83
3.39%
0.06
After Hours:
1.83
X T L Biopharmaceuticals Ltd Adr (XTLB) Stock Split History
X T L Biopharmaceuticals Ltd Adr has split its stock 2 times since its initial public offering (IPO). The first stock split occurred on October 04, 2012 with the ratio of 1-for-10, meaning that for 10 shares of XTLB owned pre-split, shareholders then owned 1 share. The most recent stock split took place on February 10, 2017 on a 1-for-5 basis.
These actions have increased XTLB stock's liquidity and made it more appealing to a larger group of investors. However, it's important to remember that a stock split only change the number of shares and the price per share with no impact on X T L Biopharmaceuticals Ltd Adr's total market capitalization.
For more detailed information of X T L Biopharmaceuticals Ltd Adr's stock splits, view the table below:
These actions have increased XTLB stock's liquidity and made it more appealing to a larger group of investors. However, it's important to remember that a stock split only change the number of shares and the price per share with no impact on X T L Biopharmaceuticals Ltd Adr's total market capitalization.
For more detailed information of X T L Biopharmaceuticals Ltd Adr's stock splits, view the table below:
XTLB stock split list
Date | Split Ratio |
---|---|
2017-02-10 | 1 - for - 5 |
2012-10-04 | 1 - for - 10 |
Will X T L Biopharmaceuticals Ltd Adr Stock Split in 2024?
The answer will depend on the decisions of the company's managers and market volatility. X T L Biopharmaceuticals Ltd Adr has not made an official announcement regarding whether it will enact a stock split or reverse stock split, but it has a history of doing so when XTLB stock prices become too high or too low for retail investors. Therefore, the ultimate decisions will certainly be made by X T L Biopharmaceuticals Ltd Adr's board of directors. Typically, no action is taken until its price per share reaches a specific threshold.
Stock Splits of Industry Leaders
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):